Skip to content
karyopharm-logo Logo for Karyopharm
Main Menu
  • Contact
  • Clinical Trials
  • Careers
  • Follow Us
  • LinkedIn
  • Twitter
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Grants and Giving
    • Careers
      • Our Culture
      • Benefits
      • Job Opportunities
  • Technology & Research
    • Overview
    • Disease Areas of Focus: Hematologic Malignancies & Solid Tumors
      • Multiple Myeloma
      • DLBCL
    • SINE Technology (Selective Inhibitor of Nuclear Export)
    • Supporting Medical Research
    • Publications and Presentations
  • Products
  • Pipeline
    • Overview
    • Oral Selinexor
    • Oral Eltanexor
    • Oral Dual Inhibitor of PAK4 and NAMPT (KPT-9274)
    • Oral Verdinexor
    • Expanded Access
  • Media Center
  • Investors
    • Company Overview
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • SEC Filings
      • Annual Reports & Proxy Statements
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • Analyst Coverage
    • Investor Alerts
    • Press Releases
    • Contact Us
      • Investor FAQs
      • RSS
  • Resources
    • Patient Resources
    • Healthcare Provider Resources

Resources

Paper

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

  • External Link
Read More
Presentation

Results of the Pivotal STORM Study (Part 2): Deep and Durable Responses with Oral Selinexor plus Low Dose Dexamethasone in Patients with Penta-Exposed and Triple Class Refractory MM

  • PDF (977.89 KB)
Read More
Presentation

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome(SDd) in Patients with Multiple Myeloma Previously Treated with PIs and IMiDs: Results of Phase 1b/2 Study of SDd

  • PDF (521.56 KB)
Read More
Presentation

Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

  • PDF (1.45 MB)
Read More
Presentation

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b SADAL Study

  • PDF (1.36 MB)
Read More
Presentation

Selinexor, a First-in-Class XP01 Inhibitor, is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents

  • PDF (1.32 MB)
Read More
Presentation

Phase I Trial of the Selective Inhibitor of Nuclear Export, SELINEXOR, in Relapsed Childhood Leukemia

  • PDF (2.62 MB)
Read More
Presentation

Final Results from a Phase I Trial Combining Selinexor with High-dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

  • PDF (333.28 KB)
Read More
Presentation

Efficacy of Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma: Results of the Pivotal STORM Part II Study

  • PDF (1.97 MB)
Read More
Presentation

A Phase 1b study using the combination of selinexor, daratumumab, and dexamethasone in multiple myeloma patients previously exposed to proteasome inhibitors and immunomodulatory drugs

  • PDF (556.14 KB)
Read More
1 2 3 … 22 Next
© Karyopharm, 2021. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Site Map